Patent Application
20180161421
The present invention relates to prophylactic agents and therapeutic agents for highly pathogenic H5N1 avian influenza virus (H5N1 HPAIV) infection and pandemic H1N1 influenza virus (H1N1 (2009) pdm) infection that are causative of onset of symptoms of novel influenza. More particularly, the present invention relates to recombinant vaccinia viruses that can express hemagglutinin (HA) protein genes of H5N1 HPAIV and H1N1 (2009) pdm, and to a prophylactic agent and a therapeutic agent for novel influenza comprising said recombinant vaccinia virus.
A patient infected with highly pathogenic H5N1 avian influenza virus (H5N1 HPAIV) was first reported in 1997, and after that the number of infected patients expanded around China, Southeast Asia and the Middle East. So far, 500 patients were taken to the hospitals and treated in high care units but 296 patients, i.e., about 60%, died. Currently, H5N1 HPAIV vaccines, i.e., inactivated whole-virus vaccines of viruses infecting/grown in embryonated chicken eggs are produced and stockpiled in anticipation of an epidemic strain as prepandemic vaccines for four clades (clades 1, 2.1, 2.2 and 2.3). H5N1 HPAIV infection of embryonated chicken eggs, however, is highly deadly and low in virus yield and thus has disadvantages such as difficulty in bulk preparation. Moreover, since the storage life is three years, products are exceeding their storage life sequentially from those produced in 2006. Prepandemic H5N1 vaccine was not produced in fiscal 2009 due to the H1N1 (2009) pdm pandemic. In addition, since vaccines are produced just in anticipation of epidemic strain, there are numbers of unclear points as to whether or not the vaccines can exert vaccine effects against the actual epidemic strains.
Meanwhile, the pandemic H1N1 influenza virus (H1N1 (2009) pdm) that seems to be originated in Mexico in April, 2009 greatly differs from the past seasonal influenza viruses in terms of antigenicity and thus infection rapidly spread around the world since large number people did not have immunity to this virus. H1N1 (2009) pdm vaccine is an inactivated split vaccine that is produced by the same method as the seasonal influenza vaccine. Since this split vaccine is also an inactivated vaccine, it does not necessarily exert vaccine effect against the epidemic strain.
Currently, Tamiflu and Relenza that inhibit the action of neuraminidase (NA) that is important to budding of influenza viruses are known as influenza therapeutic agents, but their effects are limited since, for example, it is important to administer them within 48 hours following the onset of symptoms. Intravenous agents of NA inhibitors and polymerase inhibitors for influenza viruses are also under development but they are yet at the clinical trial stage as of now.
Under the current situation, there is a strong demand for establishment of a prophylactic agent and a therapeutic agent that can exert long-term effect against a wide range of influenza viruses whose epidemics are hard to predict.
Prepandemic H5N1 HPAIV vaccines produced/stockpiled in Japan have been subjected to three types of clinical trials, namely, “safety test” conducted on 6000 people from 2008 to 2009, “initial vaccination test” conducted on 200 people, and “booster vaccination test” conducted on 200 people who had already underwent initial vaccination. In regard to safety, it was found to be within the scope of the assumption. On the other hand, although cross-reactivity was confirmed in the “booster vaccination test” where subjects initially vaccinated with “Vietnam strain” H5N1 vaccine were given different vaccine strains, i.e., Indonesia strain or Anhui strain, induction of neutralizing antibodies against different virus strains was reported to be insufficient in the “initial vaccination test” where two doses of same vaccines were administered at a 3-week interval. Moreover, report of an experiment on protection against infection using mouse models also says that cross-reactivity was particularly low between clades 2.2 and 2.3 of the subtype among these four types of vaccines prepared by the same procedure in laboratory level, and fatality was not completely prevented (Muarakami S. et al., Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model, Vaccine, vol. 26(50), p. 6398-6404, 2008).
The objective of the present invention is to provide a therapeutic agent and a prophylactic agent comprising a recombinant vaccinia virus that is effective in inhibiting the onset of symptoms caused by infection with novel influenza viruses including H5N1 HPAIV and H1N1 (2009) pdm.
The present inventors have underwent further research based on the above-described results from analyses and reviews of the novel influenza virus infection, and as a result of which came round to the idea that the use of a recombinant vaccinia vaccine that brings about strong immune activation can lead to a potent method for preventing infection with a novel influenza virus. Furthermore, in order to solve the above-described problems, the present inventors have gone through intensive study. As a result, they succeeded in preparing a recombinant vaccinia virus that was effective in inhibiting the onset of symptoms caused by H5N1 HPAIV and H1N1 (2009) pdm infections. In particular, a H5N1 HPAIV recombinant vaccinia virus was confirmed to prevent the onset of symptoms against challenge infection with a strain of a different clade at a single-dose vaccination, thereby accomplishing the present invention.
That is to say, the present invention is as follows.
(1) A recombinant vaccinia virus comprising an expression promoter and the entire or a part of cDNA coding for hemagglutinin (HA) protein of the highly pathogenic H5N1 avian influenza virus (H5N1 HPAIV) or the pandemic H1N1 influenza virus (H1N1 (2009) pdm).
An example of the vaccinia virus includes LC16m8 strain. Examples of the highly pathogenic H5N1 avian influenza virus include virus strains belonging to subtype H5, specifically, virus strains belonging to clade 1 of subtype H5, clade 2.1 of subtype H5, clade 2.2 of subtype H5 and clade 2.3 of subtype H5 while examples of the pandemic H1N1 influenza virus include virus strains belonging to subtype H1.
Examples of cDNA coding for the above-mentioned HA protein include DNAs (a) to (j) below:
(a) DNA having the nucleotide sequence represented by SEQ ID NO: 1 (sequence of clade 1 of subtype H5; Vietnam strain);
(b) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:1 under stringent conditions and that codes for HA protein of a virus strain belonging to clade 1 of subtype H5;
(c) DNA having the nucleotide sequence represented by SEQ ID NO:2 (sequence of clade 2.1 of subtype H5; Indonesia strain);
(d) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:2 under stringent conditions and that codes for HA protein of a virus strain belonging to clade 2.1 of subtype H5;
(e) DNA having the nucleotide sequence represented by SEQ ID NO:3 (sequence of clade 2.2 of subtype H5; vaccine strain of Qinghai strain);
(f) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:3 under stringent conditions and that codes for HA protein of a virus strain belonging to clade 2.2 of subtype H5;
(g) DNA having the nucleotide sequence represented by SEQ ID NO:4 (sequence of clade 2.3 of subtype H5; Anhui strain);
(h) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:4 under stringent conditions and that codes for HA protein of a virus strain belonging to clade 2.3 of subtype H5;
(i) DNA having the nucleotide sequence represented by SEQ ID NO:5 (sequence of subtype H1; vaccine strain of California strain); and
(j) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:5 under stringent conditions and that codes for HA protein of a virus strain belonging to subtype H1.
Furthermore, an example of the expression promoter contained in the recombinant vaccinia virus of the present invention includes a hybrid promoter. Specific examples of the hybrid promoter include those having either DNA (a) or (b) below:
(a) DNA having the nucleotide sequence represented by SEQ ID NO:6; or
(b) DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:6 under stringent conditions and that has a promoter activity.
(2) A pharmaceutical composition comprising the recombinant vaccinia virus according to (1) above.
The pharmaceutical composition may be used as a prophylactic agent and/or a therapeutic agent for novel influenza, specifically, as a prophylactic agent and/or a therapeutic agent for highly pathogenic H5N1 avian influenza or pandemic H1N1 influenza.
Hereinafter, a recombinant vaccinia virus of the present invention and applications thereof will be described in detail. The scope of the present invention should not be limited to these descriptions and the present invention may appropriately be modified and carried out in a way other than the following examples without departing from the spirit of the present invention. The specification of Japanese Patent Application No. 2010-233064 (filed on Oct. 15, 2010) that serves as the basis of priority claimed by the present application is incorporated herein in its entirety. In addition, patent documents, non-patent documents and other publications cited herein are incorporated herein by reference.
1. Summary of the Invention
Among various vaccines, live vaccines are some of the particularly effective vaccines. In general, development of an attenuated vaccine for an emerging virus is known to require a quite long time, which is considered to the same for novel influenzas.
One of known techniques employed in such a case is a genetic engineering technique for preparing a recombinant vaccinia virus (RVV) as a live vaccine. For example, the recombinant vaccinia viruses for rabies virus or rinderpest developed by the present inventors have been demonstrated to exert excellent effect in preventing onset of symptoms caused by infection in field tests and the like (see, for example, Tsukiyama K. et al., Arch. Virol., 1989, vol. 107, p. 225-235).
Moreover, the present inventors has succeeded in preparing a recombinant vaccinia virus having cDNA of SARS-CoV known as a pathogen of atypical pneumonia SARS (WO 2006/038742), and confirmed that it is a formulation that has an excellent prevention effect and that can be used for repeated administration (see, for example, Kitabatake M. et al., Vaccine, 2007, vol. 25, p. 630-637).
A vaccinia virus that is used as a recombinant parent for RVV preparation needs to be a vaccine strain whose safety is ensured. Vaccinia virus LC16m8 strain is known as such a vaccine strain (see, for example, Clinical Virology, vol. 3, No. 3, p. 269, 1975). LC16m8 strain that is isolated from Lister strain is the only vaccine strain currently produced and has actually been administered as a prophylactic vaccine and which has confirmed of its safety and effectiveness. The present inventors also found, in the course of developing and studying a recombinant vaccinia virus for rinderpest, HIV, SARS-CoV and the like that use of gene expression promoter that can greatly enhance antibody-producing capacity and capacity of inducing cell-mediated immunity is beneficial for a vaccinia virus of the present invention. Specifically, they found that pSFJ1-10 or pSFJ2-16 can preferably be used as a plasmid vector (see, for example, Jin N-Y et al., Arch. Virol., 1994, vol. 138, p. 315-330; Elmowalid G A. et al., Pros. Natl. Acad. Sci., 2007, vol. 104, p. 8427-8432; Arch. Virol., vol. 138, p. 315-330, 1994; Japanese Laid-Open Patent Application No. 6-237773).
As a result, the present inventors succeeded in preparing a recombinant vaccinia virus that expresses HA protein derived from H5N1 HPAIV or H1N1 (2009) pdm by integrating, into a vaccinia virus, a gene coding for hemagglutinin (HA) protein of highly pathogenic H5N1 avian influenza virus (H5N1 HPAIV) or pandemic H1N1 influenza virus (H1N1 (2009) pdm) together with an expression promoter.
A virus that serves as a parent of a recombinant vaccinia virus of the present invention is vaccinia virus as described above. cDNA (entire or a part thereof) coding for HA protein of H5N1 HPAIV or H1N1 (2009) pdm is integrated into the genome of this vaccinia virus so as to give a recombinant vaccinia virus of the present invention. Each of the cDNAs (the entire or a part thereof) coding for HA protein of H5N1 HPAIV or H1N1 (2009) pdm was used as an expression unit and introduced into a vaccinia virus vector. This expression unit was introduced into an HA gene region of vaccinia virus LC16m8 strain. Since introduction of a foreign gene into the HA gene region has no influence on the proliferative activity of the vaccinia virus, use of a safe vaccine strain with weak proliferative capacity as a parent virus of a recombinant virus is already known (see Vaccine, vol. 12, p. 675-681, 1994).
Live recombinant vaccinia vaccines for rabies virus and rinderpest virus have been field-tested and proved of their excellent effect in preventing onset of symptoms caused by infection.
The present inventors inserted HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm downstream from the hybrid promoter so as to integrate these genes into the HA protein gene region of the attenuated vaccinia virus strains LC16m8, thereby preparing recombinant vaccinia viruses (RVV). The hybrid promoter includes a poxvirus A-type inclusion (ATI) promoter and tandemly repeated vaccinia virus 7.5 kDa protein (p7.5) early expression promoter (see Jin N-Y et al., Arch. Virol., 1994, vol. 138, p. 315-330). This promoter was developed by and available from Dr. Hisatoshi Shida at Hokkaido University.
When the prepared RVV derived from LC16m8 strain was used to infect animal cells, abundant expression of HA protein of H5N1 HPAIV or H1N1 (2009) pdm was confirmed, while when the prepared RVV was used to vaccinate an individual animal, early production of antibodies with high titer against HA protein of H5N1 HPAIV or H1N1 (2009) pdm was confirmed, thereby accomplishing the present invention.
2. Preparation of Recombinant Vaccinia Virus Having HA Protein Gene of Novel Influenza Virus
HA protein genes of H5N1 HPAIV and H1N1 (2009) pdm are already registered with GenBank database (http://www.ncbi.nlm.nih.gov/genbank/) provided by the National Center for Biotechnology Information (NCBI) under designated Accession Numbers. For example, a gene coding for HA protein derived from clade 1 of H5N1 HPAIV (virus strain belonging to clade 1 of subtype H5) (cDNA: SEQ ID NO: 1) has been registered under GenBank Accession No. EF541402, a gene coding for HA protein derived from clade 2.1 of H5N1 HPAIV (virus strain belonging to clade 2.1 of subtype H5) (cDNA: SEQ ID NO:2) has been registered under GenBank Accession No. EF541394, and a gene coding for HA protein derived from clade 2.3 of H5N1 HPAIV (virus strain belonging to clade 2.3 of subtype H5) (cDNA: SEQ ID NO:4) has been registered under GenBank Accession No. DQ371928. In addition, a gene coding for HA protein derived from H1N1 (2009) pdm (virus strain belonging to subtype H1) (cDNA: SEQ ID NO:5) has been registered under GenBank Accession No. FJ969540.
Genes (cDNAs) coding for HA protein contained in a recombinant vaccinia virus of the present invention may be the above-mentioned genes as well as a part or a variant sequence thereof. For example, a gene (cDNA) coding for HA protein of clade 1 of H5N1 HPAIV may be DNA having a part of the nucleotide sequence represented by SEQ ID NO:1 deleted (specifically, DNA having the nucleotide sequence represented by SEQ ID NO:12); a gene (cDNA) coding for HA protein of clade 2.1 of H5N1 HPAIV may be DNA having a part of the nucleotide sequence represented by SEQ ID NO:2 deleted (specifically, DNA having the nucleotide sequence represented by SEQ ID NO: 13), and a gene (cDNA) coding for HA protein of clade 2.3 of H5N1 HPAIV may be DNA having a part of the nucleotide sequence represented by SEQ ID NO:4 deleted (specifically, DNA having the nucleotide sequence represented by SEQ ID NO:14). Furthermore, a gene (cDNA) coding for HA protein of H1N1 (2009) pdm may be DNA having a part of the nucleotides of DNA having the nucleotide sequence represented by SEQ ID NO:5 mutated (substitutional mutation) (specifically, DNA having the nucleotide sequence represented by SEQ ID NO:15). As a gene coding for HA protein derived from clade 2.2 of H5N1 HPAIV (virus strain belonging to clade 2.2 of subtype H5), a gene having a part of the gene (cDNA) deleted (cDNA: SEQ ID NO:3) has been registered under GenBank Accession No. DQ659327.
These HA protein genes (including partially deleted/mutated genes) have already been cloned and inserted into plasmids. Therefore, a gene contained in a recombinant vaccinia virus of the present invention, namely, the entire or a part of cDNA coding for HA protein of H5N1 HPAIV or H1N1 (2009) pdm (including variant sequences) can be obtained by a general genetic engineering procedure. For example, a nucleic acid synthesis method using a DNA synthesizer, a generally employed genetic engineering procedure, can be employed. Alternatively, a PCR technique in which a gene sequence is isolated or synthesized as a template, primers specific to each gene are designed and the gene sequence is amplified using a PCR device, or a gene amplification method using a cloning vector can be employed. The above-described methods can be carried out with reference to “Molecular cloning, A Laboratory Manual 2nd ed.” (Cold Spring Harbor Laboratory Press (1989)) and the like. The resulting PCR product may be purified by a known method. Variant sequences, in particular, substitutionally mutated DNAs, may be prepared, for example, according to site-directed mutagenesis described in “Molecular cloning, A Laboratory Manual 2nd ed.” mentioned above, “Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997)”, or the like. Specifically, preparation can be carried out by using a mutagenesis kit that makes use of site-directed mutagenesis according to a known technique such as Kunkel method or Gapped duplex method. Preferable examples of such kit include QuickChange™ Site-Directed Mutagenesis Kit (from Stratagene), GeneTailor™ Site-Directed Mutagenesis System (from Invitrogen) and TaKaRa Site-Directed Mutagenesis System (Mutan-K, Mutan-Super Express Km, etc.: from Takara Bio).
In a preferable embodiment of the present invention, HA protein gene of H5N1 HPAIV or HA protein gene of H1N1 (2009) pdm inserted into the above-described plasmid can be used as a template for the above-described PCR. Then, PCR is performed using cDNA of HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm as a template and primers specific to each gene so as to prepare an HA protein gene region of H5N1 HPAIV or H1N1 (2009) pdm. According to the present invention, a gene coded by DNA having the nucleotide sequence represented by SEQ ID NO:12 is referred to as “mCl 1” as a gene coding for HA protein derived from clade 1 of H5N1 HPAIV (virus strain belonging to clade 1 of subtype H5), a gene coded by DNA having the nucleotide sequence represented by SEQ ID NO:13 is referred to as “mCl 2.1” as a gene coding for HA protein derived from clade 2.1 of H5N1 HPAIV (virus strain belonging to clade 2.1 of subtype H5), a gene coded by DNA having the nucleotide sequence represented by SEQ ID NO:3 is referred to as “mCl 2.2” as a gene coding for HA protein derived from clade 2.2 of H5N1 HPAIV (virus strain belonging to clade 2.2 of subtype H5), a gene coded by DNA having the nucleotide sequence represented by SEQ ID NO: 14 is referred to as “mCl 2.3” as a gene coding for HA protein derived from clade 2.3 of H5N1 HPAIV (virus strain belonging to clade 2.3 of subtype H5), and a gene coded by DNA having the nucleotide sequence represented by SEQ ID NO:15 is referred to as “mIVR153” as a gene coding for HA protein derived from H1N1 (2009) pdm (virus strain belonging to subtype H1).
According to the present invention, other than DNAs having the nucleotide sequences represented by SEQ ID NOS:1-5 and 12-15, following DNAs can also be used as DNAs of the above-mentioned HA protein genes (e.g., mCl 1, mCl 2.1, mCl 2.2, mCl 2.3 and mIVR153):
DNA (mutant DNA) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: under stringent conditions and that codes for HA protein derived from clade 1 of H5N1 HPAIV;
DNA (mutant DNA of mCl 1) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:12 under stringent conditions and that codes for HA protein derived from clade 1 of H5N1 HPAIV;
DNA (mutant DNA) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:2 under stringent conditions and that codes for HA protein derived from clade 2.1 of H5N1 HPAIV;
DNA (mutant DNA of mCl 2.1) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 13 under stringent conditions and that codes for HA protein derived from clade 2.1 of H5N1 HPAIV;
DNA (mutant DNA of mCl 2.2) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:3 under stringent conditions and that codes for HA protein derived from clade 2.2 of H5N1 HPAIV;
DNA (mutant DNA) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:4 under stringent conditions and that codes for HA protein derived from clade 2.3 of H5N1 HPAIV;
DNA (mutant DNA of mCl 2.3) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:14 under stringent conditions and that codes for HA protein derived from clade 2.3 of H5N1 HPAIV;
DNA (mutant DNA) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:5 under stringent conditions and that codes for HA protein derived from H1N1 (2009) pdm (mutant DNA); and
DNA (mutant DNA of mIVR153) that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 15 under stringent conditions and that codes for HA protein derived from H1N1 (2009) pdm.
Each of the above-described mutant DNAs can be obtained by chemical synthesis or can be obtained from cDNA library or genomic library by a known hybridization technique such as colony hybridization, plaque hybridization or Southern blotting by using DNA having the nucleotide sequence represented by SEQ ID NO:1-5 or 12-15 or a fragment thereof as a probe. Stringent conditions in the above-described hybridization include, for example, 0.1×SSC to 10×SSC, 0.1% to 1.0% SDS and 20° C. to 80° C., more specifically, conditions include prehybridization at 37° C. to 56° C. for 30 minutes or longer followed by one to three times of washing with 0.1×SSC, 0.1% SDS at room temperature for 10-20 minutes. For detailed procedure of the hybridization method, see, for example, “Molecular Cloning, A Laboratory Manual 2nd ed.” (Cold Spring Harbor Press (1989)) or the like.
Moreover, DNA (mutant DNA) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:1 and coding for HA protein derived from clade 1 of H5N1 HPAIV, DNA (mutant DNA of mCl1) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:12 and coding for HA protein derived from clade 1 of H5N1 HPAIV, DNA (mutant DNA) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:2 and coding for HA protein derived from clade 2.1 of H5N1 HPAIV, DNA (mutant DNA of mCl2.1) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:13 and coding for HA protein derived from clade 2.1 of H5N1 HPAIV, DNA (mutant DNA of mCl2.2) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:3 and coding for HA protein derived from clade 2.2 of H5N1 HPAIV, DNA (mutant DNA) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:4 and coding for HA protein derived from clade 2.3 of H5N1 HPAIV, DNA (mutant DNA of mCl2.3) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO: 14 and coding for HA protein derived from clade 2.3 of H5N1 HPAIV, DNA (mutant DNA) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:5 and coding for HA protein derived from H1N1 (2009) pdm, DNA (mutant DNA of mIVR153) having 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more or 99% or more homology with the nucleotide sequence represented by SEQ ID NO:15 and coding for HA protein derived from H1N1 (2009) pdm can be used.
The expression promoter contained in the recombinant vaccinia virus of the present invention is inserted within the hemagglutinin (HA) gene region of the vaccinia virus and is a hybrid promoter consisting of a poxvirus A-type inclusion (ATI) promoter and a tandemly repeated vaccinia virus 7.5 kDa protein (p7.5) early expression promoter. This promoter can be linked to an appropriate plasmid and, for example, pBMSF7C is known (see Arch. Virol. vol. 138, p. 315-330, 1994; and Japanese Laid-Open Patent Application No. 6-237773).
A nucleotide sequence of a hybrid promoter that can be used with the present invention is represented by SEQ ID NO:6. According to the present invention, however, other than DNA having the nucleotide sequence represented by SEQ ID NO:6, DNA that hybridizes to DNA having a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO:6 and that has a promoter activity may also be used as an expression promoter (particularly, a hybrid promoter). The “stringent conditions” are the same as described above. The phrase “having a promoter activity” means that having an activity of transcribing a gene coding for a structural protein or a non-structural protein.
A protein can be mass-expressed by this hybrid promoter in a completely sugar-modified form from early to late vaccinia virus infection. According to the present invention, a plasmid vector having HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm inserted downstream from promoter pBMSF7C is called pBMSF7C-mCl1, pBMSF7C-mCl2.1, pBMSF7C-mCl2.2, pBMSF7C-mCl2.3 or pBMSF7C-mIVR153.
A recombinant vaccinia virus can be prepared by introducing any of these plasmid vectors into a vaccinia virus as a host. Introduction of a plasmid vector into a host can be carried out by employing any known procedure. For example, plasmid vector pBMSF7C-mCl1, pBMSF7C-mCl2.1, pBMSF7C-mCl2.2, pBMSF7C-mCl2.3 or pBMSF7C-mIVR153 can be introduced into an animal cell infected with attenuated vaccinia virus LC16m8 strain so as to induce homologous recombination in the hemagglutinin (HA) gene region of the vaccinia virus to prepare a recombinant vaccinia virus expressing HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm (RVV-Flu HA (H5-mCl1), RVV-Flu HA (H5-mCl2.1), RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) or RVV-Flu HA (H-mIVR153)).
Vaccinia virus LC16m8 strain used for preparing RVV can be amplified in an animal individual, but it is an attenuated strain that has extremely low proliferative property in the nerve cells. It is approved as a smallpox vaccine in Japan and no serious side effect has occurred from vaccination of about 50,000 children (see Report from the Research Group for Smallpox, Ministry of Health, Labour and Welfare: Clinical Virology, vol. 3, No. 3, 269, 1975). On the other hand, immune-inducing capacity of LC16m8 strain has been reported to be equivalent to that of the parent strain thereof, i.e., Lister strain, and thus LC16m8 strain is a safe and effective vaccine.
Since HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm is inserted into the HA protein gene region of the prepared recombinant vaccinia virus (RVV-Flu HA (H5-mCl1), RVV-Flu HA (H5-mCl2.1), RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) or RVV-Flu HA (H1-mIVR153)), expression of the HA protein derived from the vaccinia virus is absent. While influenza virus-derived HA protein causes agglutination of guinea pig erythrocytes, vaccinia virus-derived HA protein does not cause agglutination of guinea pig erythrocytes. Accordingly, RVV is screened by infecting animal cells with RVV-Flu HA (H5-mCl1), RVV-Flu HA (H5-mCl2.1), RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) and RVV-Flu HA (H1-mIVR153) so as to use agglutination of guinea pig erythrocytes on the resulting plaque as an indicator. The RVV of interest can be obtained by screening a red plaque that has erythrocyte agglutinating activity.
Introduction of HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm in the viruses obtained from the red plaque can be confirmed by performing PCR using a virus genome as a template and primers specific to HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm.
Expression of HA protein of H5N1 HPAIV or H1N1 (2009) pdm can be confirmed by Western blotting using animal cells infected with RVV-Flu HA (H5-mCl1), RVV-Flu HA (H5-mCl2.1), RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) or RVV-Flu HA (H1-mIVR153) as samples. The antibody may be rabbit antiserum prepared by immunizing a HA peptide derived from HA protein of H5N1 HPAIV (a.a. 198-217 (SEQ ID NO:10), etc.) or a HA peptide derived from HA protein of H1N1 (2009) pdm (a.a. 223-234 (SEQ ID NO:11), etc.).
Other than HA protein gene region, thymidine kinase (TK) gene region is generally used as the insertion site for gene of interest upon preparation of RVV. However, insertion of gene of interest into the TK gene region is known to cause expression defect of TK, which reduces the proliferative property of RVV. On the other hand, expression defect of HA protein is reported to have little impact on the proliferative property of RVV (see Vaccine, vol. 12, p. 675-681, 1994). Hence, according to the present invention, HA protein gene region is preferable as the insertion site for the gene of interest.
3. Pharmaceutical Composition for Preventing and Treating Novel Influenza
The present invention provides a prophylactic agent and a therapeutic agent (prophylactic and therapeutic pharmaceutical composition) for novel influenza (i.e., highly pathogenic H5N1 avian influenza and pandemic H1N1 influenza), comprising the above-described recombinant vaccinia virus. The present invention can also provide a method for preventing and treating the above-mentioned novel influenza comprising a step of administering the above-described recombinant vaccinia virus into a patient (subject), use of the above-described recombinant vaccinia virus for preventing and treating the above-mentioned novel influenza, and use of the above-described recombinant vaccinia virus for producing a prophylactic agent and a therapeutic agent for the above-mentioned novel influenza.
A pharmaceutical composition of the present invention may be introduced into an organism by any known method, for example, by intramuscular, intraperitoneal, intradermal or subcutaneous injection; nasal, buccal or lung inhalation; or oral administration. Additionally, the recombinant vaccinia virus contained in the pharmaceutical composition of the present invention may be used in combination with an existing antiviral drug (e.g., Tamiflu or Relenza). An embodiment of combinational use is not particularly limited, and the recombinant vaccinia virus of the present invention can be administered simultaneously with an existing antiviral drug, or they may be introduced into an organism according to a method in which one is administered after the other after a certain period of time.
Furthermore, a pharmaceutical composition of the present invention may also be blended with a known pharmaceutically acceptable carrier such as an excipient, a bulking agent, a binder or a lubricant, a buffer, a tonicity agent, a chelating agent, a colorant, a preservative, a fragrance, a flavoring agent, a sweetener or the like.
A pharmaceutical composition of the present invention may orally or parenterally be administered according to its form including oral agents such as a tablet, a capsule, a powdered agent, a granular agent, a pill, a solution, syrup or the like, or parenteral agents such as an injection, a topical agent, a suppository or an eye drop. Preferable examples include local injections such as intradermal, intramuscular and intraperitoneal injections.
Although a dosage may appropriately be chosen according to the type of the active element, administration route, subject of administration, age, weight or sex of the patient, symptoms and other conditions, the daily dosage of the virus is about 1000-1000000000 PFU (plaque forming units) and preferably about 100000-100000000 PFU in the case of oral administration, while it is about 100-1000000000 PFU and preferably about 1000-100000000 PFU in the case of parenteral administration. The virus may be administered once or several times a day.
The recombinant vaccinia virus of the present invention is used as a vaccine for preventing or treating novel influenza. So far, development of a vaccine against H5N1 HPAIV or H1N1 (2009) involved research focusing on antibodies against H5N1 HPAIV or H1N1 (2009) pdm and cytotoxic T cells (CTL). Accordingly, it is preferable that the antibody titer or the cell-mediated immunity activity as a vaccine is measured beforehand.
For example, the antibody titers against the prepared recombinant vaccinia viruses (RVV-Flu HA (H5-mCl1), RVV-Flu HA (H5-mCl2.1), RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) and RVV-Flu HA (H1-mIVR153)) or parent LC16m8 strain can be obtained by immunizing mice with these virus strains, collecting the sera over time, and determining ELISA values against HA protein of H5N1 HPAIV or H1N1 (2009) pdm in the sera. In the sera of mice immunized with RVV-Flu HA (H5-mCl2.2) and RVV-Flu HA (H5-mCl2.3), antibody titers against HA protein of H5N1 HPAIV increased after a week following the immunization, whereas antibody titer against HA protein of H1N1 (2009) pdm in the sera of mice immunized with RVV-Flu HA (H1-mIVR153) increased after two weeks following the immunization.
Accordingly, the recombinant vaccinia viruses (collectively referred to as “Flu HA-RVVs”) prepared by the present inventors are capable of inducing humoral immune against novel influenza.
Hereinafter, the present invention will be described more specifically by means of examples. These examples are for illustration only and shall not limit the scope of the present invention.
The HA protein gene of either H5N1 HPAIV (clade 1, clade 2.1, clade 2.2, clade 2.3) or H1N1 (2009) pdm was integrated into the SbfI-SgfI site of pBMSF7C plasmid (see Japanese Laid-Open Patent Application No. 6-237773) so as to prepare plasmid vectors pBMSF7C-mCl1, pBMSF7C-mCl2.1, pBMSF7C-mCl2.2, pBMSF7C-mCl2.3 and pBMSF7C-mIVR153 in which each of the above-mentioned HA protein genes was inserted downstream from the ATI/p7.5 hybrid promoter within the hemagglutinin (HA) gene region (
Primary cultured kidney cells were seeded onto a 35 mm dish. Once the cells reached confluence, the attenuated vaccinia virus LC16m8 strain was infected at moi=10 and 30° C. for an hour. Here, moi (multiplicity of infection) refers to PFU (plaque forming units) per cell. Following infection, the virus solution was removed by suction and the cells were washed with PBS(−). Then, after treatment with 5-fold diluted TrypLE/0.5 mM EDTA/PBS(−) and washing with 10% FCS/DMEM antibiotic (−) medium, PBS(−) and HeBS buffer, the cells were suspended in 600 μl of HeBS buffer. 1.5 μg each of plasmid vectors pBMSF7C-mCl1, pBMSF7C-mCl2.1, pBMSF7C-mCl2.2, pBMSF7C-mCl2.3 and pBMSF7C-mIVR153 was diluted with an HeBS buffer to a total amount of 30 μl, which was added to and mixed with the cell suspension and left to stand on ice for 10 minutes. The cell suspension added with the plasmid vector was suctioned with a 10 μl chip-like gold electrode and subjected to electroporation using an electroporator (from Invitrogen) (1200 V; pulse width: 40 ms; and number of pulse: 1). Following electroporation, the resultant was immediately added to RK13 cells or the primary cultured kidney cells that had been seeded onto a 35 mm dish with 2 ml of 10% FCS/DMEM antibiotic(−) medium beforehand. The resultant was added to the 35 mm dish in twice the amount needed for electroporation and cultured at 30° C. for 24 hours.
After 24 hours of cultivation, the cells were scraped off from the dish using a scraper and the cell suspension was collected and subjected to ultrasonication (30 sec×4 times) in cold water followed by centrifugation (2000 rpm, 10 min). The resulting supernatant was used as a virus solution. The virus solution was diluted in 5% FCS/MEM medium and used to infect the primary cultured kidney cells that had been seeded onto a 150 mm dish at 30° C. for an hour. The virus solution was removed by suction and then the cells were washed with PBS(−). 5% FCS/0.5% methylcellulose/MEM medium was added and the resultant was cultured at 30° C. for 96 hours. After 96 hours of cultivation, the supernatant was removed by suction and washed with PBS(−). A PBS(+)-diluted guinea pig erythrocyte solution was added to the 150 mm dish and cultured at 30° C. for 30 minutes. The erythrocyte solution was removed by suction and then the cells were washed twice with PBS(+). Plaques having the guinea pig erythrocytes adsorbed thereon were collected using Pipetman. For the collected plaques, introduction of each of the above-mentioned HA protein genes was confirmed by PCR and gene sequencing. Purification was repeated for three times for plaques in which gene transfer was confirmed.
The viruses subjected to plaque purification for three times were subjected to small-scale cultivation. The colony obtained after the third purification was suspended in 500 μl of 5% FCS/MEM medium and subjected to ultrasonication in cold water. Following centrifugation (2000 rpm, 10 min), 250 μl of the supernatant was added to the primary cultured kidney cells seeded onto a 60 mm dish for infection at 30° C. for an hour. After the infection, 2.5 ml of 5% FCS/MEM medium was added and the resultant was cultured at 30° C. for 96 hours. 96 hours later, the cells were scraped off from the flask with a scraper to collect the cell suspension. The collected cell suspension was subjected to ultrasonication (30 sec, 4 times) in cold water, followed by centrifugation. The supernatant was collected as a virus solution. The collected virus solution was serially diluted and then added to RK13 cells or the primary cultured kidney cells seeded onto a 6-well plate for infection at 30° C. for an hour. The virus solution was removed by suction and the cells were washed twice with PBS(−), to which 5% FCS/0.5% methylcellulose/MEM medium was added for cultivation at 30° C. for 96 hours. 96 hours later, the number of plaques formed in the well was counted to calculate the titer.
Based on this calculated titer, mass-scale cultivation was carried out. RK13 cells or the primary cultured kidney cells were seeded onto ten 150 mm dishes. Once the cells reached confluence, the recombinant vaccinia virus solution (2 ml) was used for infection at moi=0.1 and 30° C. for an hour. Following infection, the virus solution was removed by suction, added with 18 ml of 5% FCS/MEM medium and cultured at 30° C. for 96 hours. 96 hours later, the scraper was used to scrape off the cells from the flask and the cell suspension was collected and stored in a frozen state at −80° C. This cell suspension was subjected to a round of freeze-thaw, ultrasonication (30 sec, 4 times) in cold water and centrifugation. The supernatant was collected as a virus solution. This virus solution was serially diluted and used to infect RK13 cells or the primary cultured kidney cells seeded onto a 6-well plate so as to calculate the titer of the viruses in the solution in the same manner as described above. The virus solutions (recombinant vaccinia viruses) with calculated titers were used in various experiments as described below in the following examples.
PCR was carried out using the following primers specific to each of the HA protein genes (cDNA: SEQ ID NOS:12, 13, 3, 14 and 15) mentioned in Example 1 and the genome of the resulting recombinant vaccinia virus as a template in order to confirm whether each HA protein gene was introduced into the virus genome (
Nucleotide Sequences of Primers Used in PCR for Confirming Insert
Specifically, the composition of the reaction solution was 1 U DNA polymerase, 0.3 mM dNTP, 1 μM F-primer and 1 μM R-primer in 50 μl of a buffer attached to a commercially available polymerase. The cycle conditions were a total of 25 cycles of: denaturing at 95° C. for 0.5 minutes; annealing at 58° C. for 0.5 minutes; and elongation at 72° C. for 2 minutes. The resulting PCR product was subjected to electrophoresis using agarose gel to confirm the band. As a result, HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm was found to be introduced into the recombinant virus genome if a single band having the length anticipated by primer design was observed whereas HA protein gene of H5N1 HPAIV or H1N1 (2009) pdm was found to be not introduced if no such band was observed.
As shown in
The recombinant vaccinia virus was used to infect RK13 cells that had been seeded onto a 6-well plate beforehand at moi=10 and 30° C. for an hour. Following infection, the virus solution was removed by suction and the cells were washed once with PBS(−). To each well, 2 ml of 5% FCS/MEM medium was added for cultivation at 30° C. for 18 hours. 18 hours later, the medium was removed by suction and the cells were washed twice with PBS(−). 100 μl of lysis buffer (1% SDS, 0.5% NP-40, 0.15 M NaCl, 10 mM Tris-HCl (pH 7.4)) was added to lyse the cells, and the solution was transferred into a 1.5 ml Eppendorf tube. The collected solution was subjected to ultrasonication in cold water until zero viscosity. The amount of protein in the prepared solution was quantified according to Lowry method.
Electrophoresis was carried out for 30 μg of the protein using 10% acrylamide gel. At the end of electrophoresis, the gel was removed, and the protein in the gel was transferred onto a PVDF membrane with a semi-dry blotter by running a current at 2 mA/cm2 for 60 minutes. The membrane was washed with a TBS-T solution and immersed in a 5% skimmed milk-TBS-T solution for blocking. At the end of the blocking, the membrane was washed for three times with a TBS-T solution. The primary antibody was a rabbit polyclonal antibody against a HA peptide derived from HA protein of H5N1 HPAIV (a.a. 198-217 (SEQ ID NO:10; NDAAEQTKLYQNPTTYISVG)) or a HA peptide derived from HA protein of H1N1 (2009) pdm (a.a. 223-234 (SEQ ID NO:11; YSKKFKPEIAIR)). At the end of the reaction with the primary antibody, the membrane was washed for three times with a TBS-T solution. The secondary antibody was anti-rabbit IgG-linked HRPO (from Donkey, Amersham). At the end of the reaction with the secondary antibody, the membrane was again washed for three times with a TBS-T solution. Immobilon western detection reagent (from Millipore) was added to the membrane and the fluorescence was captured with a CCD camera for image analysis.
As a result, as shown in
The recombinant vaccinia virus obtained in Example 1 or RVV-Empty in which an empty vector had been inserted was used to immunize BALB/c mice (female) transendothelially (intradermally (i.d.)) at 1×107 PFU, and 1, 2, 3 and 4 weeks later, blood was drawn from the orbital vein. The collected blood was all placed into a 0.5 ml tube containing a serum separation agent and subjected to centrifugation (15000 rpm, 10 minutes) to separate and collect the serum. The serum stored in a frozen state at −80° C. until the subsequent ELISA test described below.
A 96-well plate was coated with HA protein of H5N1 HPAIV or H1N1 (2009) pdm, to which 100-1000-fold dilution of the frozen serum sample was added and left to stand at 4° C. overnight. The 96-well plate was washed with a TBS-T solution, and then added with anti-mouse IgG-linked HRPO (from Sheep, Amersham) as a secondary antibody. Following reaction at room temperature for 2 hours, the 96-well plate was again washed for three times with a TBS-T solution. A color development solution was added at 100 μl/well. After leaving it to stand at room temperature for 30 minutes, 2M sulfuric solution was added at 50 μl/well to terminate the reaction. Absorbance at 490 nm was read with a microplate reader.
As a result, as shown in
As shown in
In addition, it was found, from the histopathological analysis of the lungs, that the lungs of the non-vaccinated mice infected with H1N1 (2009) pdm exhibited a pneumonia image with thickened stromal cells, mucus exudation and locally filled alveolar space due to infiltration with the lymphocytes, i.e., immunocompetent cells, whereas pneumonia was found to be significantly alleviated in the vaccinated group where significant lymphocytic infiltration was observed around the bronchi, i.e., the infected site, but the alveolar space stayed clear (
Furthermore, mice subjected to single vaccination with RVV-Flu HA (H5-mCl2.2) or RVV-Flu HA (H5-mCl2.3) were subjected to challenge infection with clade 2.3 of H5N1 HPAIV after five weeks following vaccination with these recombinant vaccinia viruses (vaccines) to examine the effects of the vaccines. The challenge infection was performed at two concentrations, i.e., 1×104 PFU and 1×105 PFU. In either case of challenge infection at 1×104 PFU or 1×105 PFU, survival rates were 100% for both of the groups inoculated with RVV-Flu HA (H5-mCl2.2) and RVV-Flu HA (H5-mCl2.3), and the weights increased after three days following the influenza virus infection and rebounded to almost the same weight before the infection. Additionally, it was found, from the histopathological analysis of the lungs upon challenge infection at the higher concentration, i.e., 1×105 PFU, that the lungs of the non-vaccinated mice infected with H5N1 virus showed thickened stromal cells even in the lungs of the survived individuals, whereas pneumonia was significantly alleviated in the groups vaccinated with RVV-Flu HA (H5-mCl2.2) or RVV-Flu HA (H5-mCl2.3) where significant lymphocytic infiltration around the bronchi, i.e., the infected site, and the vessels and locally thicken stroma were observed but the alveolar space stayed relatively clear. Accordingly, the recombinant vaccinia virus (vaccine) prepared this time also showed protective effect against deadly H5N1 HPAIV infection. A sufficient vaccine effect against infection with clade 2.3 virus was also observed in the group inoculated with different clade, i.e., clade 2.2.
As the novel influenza recombinant vaccinia viruses, RVV-Flu HA (H5-mCl2.2), RVV-Flu HA (H5-mCl2.3) and RVV-Flu HA (H1-mIVR153) that express hemagglutinin (HA) protein were used (
With respect to the challenge infection with each influenza virus, reduction in weight loss and an effect in alleviating pneumonia were observed in all of the RVV-Flu HA (H5-mCl2.2)-, RVV-Flu HA (H5-mCl2.3)- and RVV-Flu HA (H1-mIVR153)-inoculated groups (
Thus, a vaccinia virus of the present invention was demonstrated to have prophylactic and therapeutic effects against novel influenza and shown to be useful as a novel influenza vaccine.
The present invention provides a highly-safe novel recombinant vaccinia virus that is effective in preventing or treating novel influenza, and a prophylactic agent or a therapeutic agent for novel influenza comprising the same (a prophylactic or therapeutic vaccine against novel influenza).
SEQ ID NO:7: Synthetic DNA
SEQ ID NO:8: Synthetic DNA
SEQ ID NO:9: Synthetic DNA
SEQ ID NO:12: Recombinant DNA
SEQ ID NO:13: Recombinant DNA
SEQ ID NO:14: Recombinant DNA
SEQ ID NO:15: Recombinant DNA
| Number | Date | Country | Kind |
|---|---|---|---|
| 2010-233064 | Oct 2010 | JP | national |
This application is a divisional of U.S. patent application Ser. No. 13/879,228, filed Apr. 12, 2013, which is the U.S. National Stage of International Application No. PCT/JP2011/074086, filed Oct. 13, 2011, which claims the benefit of priority to Japanese Application No. 2010-233064, filed on Oct. 15, 2010, the disclosures of which are incorporated by reference herein in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13879228 | Apr 2013 | US |
| Child | 15882689 | US |
